ArticleHeliyon2024
AI-based tool for early detection of Alzheimer's disease.
Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 31 citations in OpenAlex.
- LAT-BirdDrone: A dedicated dataset for high-precision classification of low-altitude small target trajectories enhanced by hybrid neural networks.Data in brief · 2026Article
- Convolutional neural networks in brain disease diagnosis: a unified review of Alzheimer's, Parkinson's, and brain tumor classification.Frontiers in neuroscience · 2026Review
- Advances in AI-based diagnosis of Alzheimer's disease using MRI: a comprehensive survey.Frontiers in medicine · 2026Review
- Multimodal neuroimaging and AI integration in cognitive disorders: advances, challenges, and future directions for precision medicine.Psychoradiology · 2026Review
- A Hybrid Explainable AI Framework (HXAI) for Accurate and Interpretable Diagnosis of Alzheimer's Disease.Diagnostics (Basel, Switzerland) · 2025Article
- Optimizing mobile cognitive assessment reduces administration time while maintaining screening accuracy in older adults.Scientific reports · 2025Article
- A Meta-Learning-Based Ensemble Model for Explainable Alzheimer's Disease Diagnosis.Diagnostics (Basel, Switzerland) · 2025Article
- Artificial Intelligence and Neuroscience: Transformative Synergies in Brain Research and Clinical Applications.Journal of clinical medicine · 2025Review
- A dual-model AI framework for Alzheimer's disease diagnosis using clinical and MRI data.Frontiers in medicine · 2025Article
- Explainable bidirectional encoder representations from image transformers for Alzheimer's disease prediction.Digital healthArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the context of Alzheimer's disease (AD), timely identification is paramount for effective management, acknowledging its chronic and irreversible nature, where medications can only impede its progression. Our study introduces a holistic solution, leveraging the hippocampus and the VGG16 model with transfer learning for early AD detection. The hippocampus, a pivotal early affected region linked to memory, plays a central role in classifying patients into three categories: cognitively normal (CN), representing individuals without cognitive impairment; mild cognitive impairment (MCI), indicative of a subtle decline in cognitive abilities; and AD, denoting Alzheimer's disease. Employing the Alzheimer's Disease Neuroimaging Initiative (ADNI) dataset, our model undergoes training enriched by advanced image preprocessing techniques, achieving outstanding accuracy (testing 98.17 %, validation 97.52 %, training 99.62 %). The strategic use of transfer learning fortifies our competitive edge, incorporating the hippocampus approach and, notably, a progressive data augmentation technique. This innovative augmentation strategy gradually introduces augmentation factors during training, significantly elevating accuracy and enhancing the model's generalization ability. The study emphasizes practical application with a user-friendly website, empowering radiologists to predict class probabilities, track disease progression, and visualize patient images in both 2D and 3D formats, contributing significantly to the advancement of early AD detection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.